Cargando…
Assessment of CareStart G6PD rapid diagnostic test and CareStart G6PD biosensor in Mauritania
BACKGROUND: The elimination of Plasmodium vivax malaria requires 8-aminoquinolines, which are contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to the risk of acute haemolytic anaemia. Several point-of-care devices have been developed to detect G6PD deficiency....
Autores principales: | Djigo, Oum Kelthoum Mamadou, Ould Khalef, Yacoub, Ould Ahmedou Salem, Mohamed Salem, Gomez, Nicolas, Basco, Leonardo, Briolant, Sébastien, Ould Mohamed Salem Boukhary, Ali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8340529/ https://www.ncbi.nlm.nih.gov/pubmed/34353361 http://dx.doi.org/10.1186/s40249-021-00889-2 |
Ejemplares similares
-
Assessment of glucose-6-phosphate dehydrogenase activity using CareStart G6PD rapid diagnostic test and associated genetic variants in Plasmodium vivax malaria endemic setting in Mauritania
por: Djigo, Oum kelthoum Mamadou, et al.
Publicado: (2019) -
Molecular Epidemiology of G6PD Genotypes in Different Ethnic Groups Residing in Saharan and Sahelian Zones of Mauritania
por: Djigo, Oum Kelthoum Mamadou, et al.
Publicado: (2021) -
Malaria in Mauritania: retrospective and prospective overview
por: Lekweiry, Khadijetou Mint, et al.
Publicado: (2015) -
Malaria prevalence in Mauritania: a systematic review and meta-analysis
por: El Moustapha, Inejih, et al.
Publicado: (2023) -
Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood
por: Bancone, Germana, et al.
Publicado: (2018)